Breast Cancer: Ribociclib with Hormone Therapy and Radiotherapy

We are studying the safety and effectiveness of Ribociclib combined with hormone therapy and radiotherapy for elderly patients with hormone-positive, HER2-negative breast cancer. This trial is for those newly diagnosed who are not ready for surgery.

>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOralEndocrinologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Kisqali
Kisqali is a medicine used to treat certain types of advanced or metastatic breast cancer by slowing cancer cell growth.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ribociclib
Ribociclib is a substance that slows growth of certain breast cancers by blocking proteins that help cancer cells divide.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Antoine Lacassagne
Medical oncology
Nice, France
Chu De Saint Etienne
Medical oncology
Saint-Étienne, France
Sponsor: Centre Antoine Lacassagne
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.